Haematopoietic SCT (HSCT) is curative for many children with primary immunodeficiencies or other nonmalignant conditions. Outcome for those admitted to intensive care following HSCT for oncology diagnoses has historically been very poor. There is no literature available specifically regarding the outcome for children with primary immunodeficiency requiring intensive care following HSCT. We reviewed our post-HSCT admission to intensive care over a 5-year period. A total of 111 children underwent HSCT. Median age at transplant was 1 year 4 months. The most common diagnosis was SCID. In all, 35% had at least one intensive care admission and 44% survived to be discharged from intensive care. Also, 73% of admission episodes requiring invasive ventilation but no inotropes or renal replacement therapy resulted in survival to discharge. Children undergoing HSCT for immunological diagnoses had a high rate of admission to intensive care. No factors were identified that could predict the need for admission. Invasive ventilation alone has a much better outcome than that in historical series. However, the need for multi-organ system support was still associated with a poor outcome. This information is useful when counselling families of children that have deteriorated and been admitted to intensive care during the HSCT procedure.
Introduction
Haematopoietic SCT (HSCT) is the only curative treatment for many children with primary immunodeficiencies (PIDs) and other non-malignant conditions. Recent advances in HSCT techniques, better recognition and management of post transplant complications and infections have improved survival for these patients treated by allogeneic HSCT. 1, 2 Improved outcome was demonstrated by the recent European data, which showed 90% survival for children with SCID undergoing HSCT with a genoidentical sibling donor and 79% survival for non-SCID primary immunodeficiency. 2 Despite these improvements, significant mortality and morbidity are associated with HSCT, and a significant proportion of patients require intensive care support during the process. There is a perception that those admitted to intensive care units (ICUs) following HSCT do badly. Recipients of allogeneic transplants are more at risk than those undergoing autologous HSCT. 3 Rates of admission to ICUs for adults and children vary between centres, but range from 11 to 44% of HSCT recipients. [4] [5] [6] [7] The reasons for ICU admission relate to well-recognised post-HSCT complications, including respiratory failure, neurological deterioration, cardiac dysfunction, sepsis and gastrointestinal bleeding. 8 These failing organ systems can be supported by a number of measures in ICU settings, including ventilation, cardiovascular support with inotropes and renal replacement therapy (RRT).
The outcome for children undergoing HSCT who require intensive care admission is worse than for those who do not require this support. A recent meta-analysis demonstrated an overall ICU mortality of 60% (ref. 9) . However, there is debate as to whether there has been a decrease in mortality for HSCT recipients admitted to ICU over recent years, with some studies showing a marked increase in survival while others showed no change. 5, 8, 9 Debate continues about the appropriate degree of intensive care support for these patients and in which circumstances. No pre-transplant characteristics have been identified that can predict a need for intensive care. Post transplant grade III-IV GVHD has been shown to be associated with increased risk of ICU admission. 3 A number of predictors of poor outcome for those admitted to ICU have been identified, including the need for mechanical ventilation. [10] [11] [12] In one early study from 1993, only 3% of those requiring mechanical ventilation survived beyond 6 months after extubation. 13 Other variables have been associated with poor outcome in adults, haemodynamic instability, gastrointestinal bleeding, infection, multi-organ failure, increased length of ICU stay and interval between transplant and ICU admission. 6, [13] [14] [15] [16] [17] In children, additional factors associated with poor prognosis include severe haemorrhagic cystitis, lung injury and failure of more than three organ systems. 18 One paediatric study has also demonstrated a difference in prognosis with different sources of stem cells. 19 Despite these concerns, children and adults undergoing HSCT continue to be admitted to ICUs. Most published data concern adult oncology patients undergoing HSCT. Limited data are available for intensive care admissions and outcomes for children with PIDs and other nonmalignant diseases. Identifying factors in these children that could predict need for ICU care and outcome once admitted to paediatric ICU (PICU) would therefore be beneficial.
We report a single-centre experience of children requiring intensive care admission while undergoing HSCT for PID or other non-malignant disorders over a 5-year period. We report their characteristics including diagnosis, transplant type and pre-existing infections, together with the reasons for admission and management required. We report outcome in terms of survival and look at factors that can predict the need for intensive care, and those that might predict the outcome once a child has been admitted to ICU.
Patients and methods

Patient identification
Newcastle is one of two UK supraregionally designated centres for HSCT for children with PIDs and severe immune dysregulation. There is an eight-bedded paediatric intensive care unit (PICU) on site. This retrospective analysis is of all patients who were planned for allogeneic HSCT between 1 January 2005 and 31 December 2009 under the care of the paediatric immunology service. Consent was obtained from all patients/parents according to local and European Group for Blood and Marrow Transplantation (EBMT) guidelines, including consent to record data for research purposes. All those who were admitted to the PICU or adult ICU were identified. There is no standardised policy for admission of HSCT patients to PICU. The need for admission is discussed on a case-bycase basis. The paediatric HSCT ward provides high dependency level care, and the need for admission to PICU is usually determined by the likely requirement for invasive ventilation, inotropes or RRT. Other high dependency therapies are provided on the HSCT ward, including care of children with tracheotomies, non-invasive ventilation and peritoneal dialysis.
Inclusion and exclusion criteria
Patients were excluded if they were admitted to ICU/PICU for a problem unrelated to the transplant process, that is, those admitted to PICU before conditioning for HSCT commenced, and who subsequently were discharged or died without receiving a transplant. Those undergoing autologous transplant were excluded. Patients were included if they received an unconditioned transplant but were admitted to ICU/PICU with a transplant-related complication, or if they were admitted to ICU/PICU during conditioning for transplant.
Data collection
The following data were collected from patient medical records: patient age at transplant, diagnosis, source (BM, PBSC or umbilical cord), donor type and conditioning regimen. Data regarding reason for admission to ICU/ PICU, timing, intensive care treatment received and outcome were collected for each admission. Reason for admission was categorised as: respiratory compromise, cardiovascular instability (hypotension requiring inotropic support, most commonly due to capillary leak), venoocclusive disease, presumed or proven infection, neurological compromise or a surgical problem. Categories were subdivided where appropriate. Patients were categorised according to whether they received invasive ventilation (via an endotracheal tube), inotropes (defined as the requirement for any inotropic agent for any length of time), RRT (most commonly using continuous veno-venous haemofiltration), a combination of the three or observation only. Other non-intensive care measures were not documented for the purpose of this report. For those that did not survive, the day of death before/after transplant, cause and place of death were documented.
Statistical analysis was performed to identify any factors that were associated with admission to PICU or predicted outcome, once a child had been admitted to intensive care. These included: sex, age less than 1 year, diagnostic category, presence or absence of infection immediately before or at the time of transplant, conditioning, reason for admission, duration of admission and PICU treatment. Pearson w 2 tests were used to compare categorical data, and Student t-tests were used for continuous data. Data were analysed using SPSS for windows release 17.0.0.2008 (SPSS Inc, Chicago, IL, USA).
Results
Characteristics of all children undergoing HSCT Over the study period 111 patients (76 males) received 128 transplants. One patient died during conditioning. A total of 12 patients required unconditioned boost transfusions and five underwent complete re-transplant. The median age at transplant was 1 year 4 months (range 1 month-19 years, 4 months). In all, 50 (45%) children were under 1 year of age. Low-resolution molecular HLA typing was performed for HLA class I and high-resolution for class II loci. All adult-matched unrelated donors were 9/10 or 10/10 matched, and cords were 8-10/10 apart from 1, which was 6/10 (4/6).
Conditioning regimens were myeloablative or reduced intensity, with or without serotherapy. Two patients received unconditioned transplants. No patients received TBI.
All patients received GVHD prophylaxis with either cyclosporin or tacrolimus with or without additional mycophenolate mofetil, MTX or prednisolone.
OS was 84/111 (76%). Three patients died but were never admitted to ICU. One was a sudden unexplained death in the community and two had intractable GVHD, for which treatment was withdrawn. Survival for patients admitted to PICU was 15/39 (38%), compared with 69/72 (96%) survival for those who were never admitted to PICU.
Characteristics of those admitted to PICU
In all, 39 (35%) patients had at least one ICU/PICU admission. One was admitted to adult ICU, 38 were admitted to PICU. Also, 27 (69%) patients had one PICU admission each, while 8 (21%) had two admissions, 1 had three admissions and 3 had four admissions. There were in total 58 admission episodes, with only one of these being to adult ICU. Henceforth, the term PICU will be used to incorporate admissions to PICU, and the single admission to the adult intensive care unit. Three patients were admitted to PICU before receiving their transplant, with one dying on the day before transplantation and two receiving their transplant in PICU. Patient characteristics are shown in Table 1 .
The median age at transplant for those admitted to PICU was 9 months (range 1 month-17 years 11 months). The median age at first admission to PICU was 1 year 2 months (range 1 month-18 years 1 month). In all, 25 (61%) were male. Age and sex were not significantly associated with need for admission to PICU. Infants (o1 year old) were not significantly more likely to be admitted to PICU. There was no significant difference between the underlying diagnoses and need for PICU admission. However, all six children with undefined T-cell disorders had at least one PICU admission.
Of the 12 who required unconditioned boost transfusions, 6 (50%) were admitted to PICU. Only one child of the five who underwent complete re-transplant was admitted to PICU.
A total of 12 children (31%) had ongoing viraemia with adenovirus, CMV, EBV or human herpes virus 6 (HHV6) immediately before or at the time of HSCT. Six (15%) had gastrointestinal viral infections such as Norovirus at or immediately before HSCT. Three children were treated for Pneumocystis jiroveci infection immediately before transplant. Two children had respiratory viruses (respiratory syncytial virus and parainfluenza). One child with chronic granulomatous disease had ongoing fungal infection at the time of HSCT. The presence of these infections was not significantly associated with admission to PICU when compared with those who did not require PICU admission.
Transplant type for those admitted to PICU Of those admitted to PICU, 38 patients underwent allogeneic transplant and one died before receiving planned allogeneic transplant. There was no significant difference in donor type or source of stem cells between those admitted and those not admitted to PICU. There was no significant difference between conditioning type (myeloablative, reduced intensity, campath alone or none) and need for admission to PICU.
Reason for admission
In all, 34 (59%) of all admission episodes were for respiratory problems, 3 (5%) for cardiovascular instability, 5 (9%) for complications related to veno-occlusive disease, 3 (5%) for presumed or proven infection, 3 (5%) for neurological problems (seizures or encephalopathy) and 10 (17%) for surgical problems. The respiratory category included respiratory failure as a result of pneumonitis (six admissions), pneumothorax (four admissions), pulmonary haemorrhage (four admissions), pulmonary hypertension (two admissions), pleural effusion (one admission), respiratory arrest (four admissions), pulmonary oedema (four admissions) and other undefined causes of respiratory deterioration (nine admissions). Surgical problems included six elective post-operative admissions following laparotomy, one elective post-operative admission following splenectomy, one elective femoral line insertion, one perforated gastric ulcer and one acute abdomen of unknown aetiology.
Timing and duration of admission
The median day for first admission to PICU was þ 31 from transplant date (range À6 to þ 834), for second admission median þ 51 (range þ 13 to þ 849), third admission þ 134 (range þ 50 to þ 168) and for fourth admission þ 176 (range þ 55 to þ 178). The median duration of admission for all episodes was 6 days. The overall mean duration of admission was 9.2 days (range 1-35 days).
PICU treatment
Of the 58 episodes of admissions, 28 (48%) were for respiratory support with invasive ventilation, 11 (19%) for support of two organ systems (invasive ventilation and inotropes or invasive ventilation and RRT) and 13 (22%) for support of three organ systems (invasive ventilation, inotropes and RRT). In all, 8 (14%) patients required no specific intensive care intervention (invasive ventilation, inotropes or RRT), but were observed for a period of time owing to concerns about potential for deterioration and imminent need for invasive ventilation or other organ system support that could not be provided on the transplant unit. Other specific therapies were continued throughout this time.
A total of 33 patients (85%) required ventilation at some point; 11 (28%) required support of two organ systems and 9 (23%) required support for three organ systems. See Figure 1 for treatment received according to reason for admission.
Outcome A total of 17 children (44%) survived to discharge from PICU, 21(54%) died in PICU and one was discharged from PICU home for palliative care. Of the 17 children who were discharged from PICU, 16 survived over 100 days after their last discharge from PICU, with one late death with withdrawal of care for intractable GVHD.
In all, 15 (35%) patients died on their first admission to PICU. Five died on their second admission, the only child that had three admissions to PICU died on the third admission and two died on their fourth admission. One child survived four admissions. For those that died, the median day before/after transplant was þ 83 (range day À3 to day þ 859). There was no significant difference between the number of admissions required and survival. There was no statistically significant difference between the mean duration of admission for survivors and non-survivors, 8.06 and 11.14 days, respectively.
One of six children who had boost transfusions survived long term. The only child admitted to PICU who underwent re-transplant died in PICU.
Those admitted with surgical problems were most likely to survive, with 9/10 (90%) surviving to discharge from PICU. In all, 20/34 (59%) of the admission episodes with respiratory compromise, 2/3 (67%) of the admissions for infection, 3/5 (60%) of the admissions for complications of veno-occlusive disease and 2/3 of those admitted with neurological problems resulted in survival to discharge. All three patients with cardiovascular instability died in PICU. There was no significant association between cause for admission to PICU and survival.
Admissions to PICU, which did not require invasive ventilation, inotropes or RRT, were most likely to result in a successful outcome, with all patients surviving to discharge. These children were admitted to PICU electively owing to concerns about the potential for deterioration; however, they did not go on to require further support. In all, 19/26 (73%) of the episodes requiring ventilation alone resulted in survival until discharge from PICU, whereas 3/9 (33%) of those requiring ventilation and inotropes and 6/13 (46%) of those requiring ventilation, inotropes and RRT were successful. Neither of the two episodes requiring ventilation and RRT resulted in survival until discharge. There was a significant association between episode maximal therapy received and survival (P ¼ 0.007). See Table 2 for episode outcome according to treatment received.
Discussion
Although a relatively large number of children were included in this series, the heterogeneity of the underlying immune defects together with the variation in complications makes analysis somewhat difficult. Over the 5-year period, 35% of all children undergoing HSCT had at least one PICU admission. This is high, but falls within the range described in other series. [4] [5] [6] It may reflect the complicated nature of patients undergoing HSCT with pre-existing infections and organ damage, which are less common in children undergoing HSCT for malignancy. On statistical analysis there was no particular underlying immune defect, pre-existing infection, transplant type or conditioning regimen associated with need for admission to PICU. This confirms the findings of other reports. However, strikingly, all six children with an undefined T-cell disorder were admitted to PICU. It is well recognised that children with undefined T-cell deficiencies are known to be at a higher risk of dying. This may be because without a clear genetic diagnosis patients are not offered HSCT as early in contrast with those with a clearly defined clinical and genetic PID, and often have pre-existing infection and organ damage before transplantation. 2 The reasons for admission to PICU were similar to those described in other series, most notably respiratory compromise. This is not surprising, as respiratory complications are common post HSCT in children, and are associated with increased mortality. 20 The majority of HSCT patients admitted to PICU received invasive ventilation (85%), but 51% also required support for other organ systems. This indicates that only the most seriously ill are transferred to PICU for intervention that cannot be given on the HSCT unit.
Mortality in children admitted to PICU was high compared with those that were not admitted. However, 41% did survive long term (4100 days after discharge), with only one late death. This is similar to the level of mortality found in a recent meta-analysis. 9 By comparison with many other studies that have suggested that invasive ventilation is a poor prognostic factor, 73% of PICU admission episodes that only required invasive ventilation resulted in survival to discharge. This is markedly higher than in historical series and reflects the results found in a more recent series of children undergoing HSCT for oncology diagnoses, which demonstrated improved survival over time for patients requiring ventilation. 21 It is well documented that respiratory status prior to transplant is a significant factor in terms of predicting outcome. 2, 22 Outcome was worse for those that needed two-organ system support. This is not surprising, as multi-organ system failure is recognised to be associated with poor outcome. 12, 23 However, those that required three-organ system support appeared to do better than those requiring invasive ventilation and RRT. This is most likely due to the small numbers involved. It is recognised that RRT is associated with poor survival in children admitted to PICU for non-HSCT-related conditions, in particular if associated with sepsis or multiorgan dysfunction. 24, 25 It has also been demonstrated that RRT is associated with poor outcome in paediatric oncology patients undergoing HSCT. 26 Although only a small number, those admitted with cardiovascular instability did particularly badly, with no survivors.
Admission to PICU for surgical reasons in non-HSCT patients is normally associated with a very good outcome. This is reflected in the patients reported here, with those going to PICU for elective surgical procedures having a good outcome. Those in this group who did not survive died from HSCT complications rather than from their surgical procedure.
Overall, more than 95% of children are discharged alive from PICU in the UK and most children spend fewer than 2 days in PICU. 27 When compared with this figure, children admitted to PICU post HSCT have far longer PICU admissions and much higher mortality than other patient groups.
Conclusion
Children undergoing HSCT for PID or other nonmalignant disorders had a high rate of PICU admission. There were no factors found to identify those at particular risk of needing PICU admission. Respiratory failure was a common reason for admission to PICU. However, this report demonstrated better survival for those requiring invasive ventilation when compared with historical series. Multi-organ system failure was associated with a poor prognosis. Of 39 children admitted to PICU, 15 (38%) survived.
Children undergoing HSCT who become increasingly unwell should continue to be offered PICU support when they can no longer be managed on a transplant unit. We can be optimistic about the outcome for those that only require respiratory support or are admitted following a surgical procedure. Those that require multi-organ support remain more of a concern. Swift action is required for any child that deteriorates during the HSCT process, with discussion with the intensive care team early. As further developments occur in the management of multi-organ failure from all causes, it is hoped that the outcome for these HSCT children will also improve. In the meantime, this information is useful in counselling families about the most appropriate course of action should their child deteriorate during the HSCT process.
